Last reviewed 2026-04-20 · How we verify

Mobuzon (MOFEBUTAZONE)

Phase 2 active Small molecule

Mobuzon (generic name: MOFEBUTAZONE) is a mofebutazone drug. It is currently in Phase 2 development.

Mofebutazone works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

Mofebutazone, also known as Mobuzon, is a small molecule drug in the mofebutazone class. Its original development is unclear, and its current owner is also unknown. The target and approved indications of Mobuzon are not specified. It is not known whether Mobuzon is FDA-approved or off-patent. Further information on its commercial status and key safety considerations is also unavailable.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MOFEBUTAZONE
Drug class	mofebutazone
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. Mofebutazone blocks these messengers, which helps to reduce pain and swelling. This can be especially helpful for people with conditions like arthritis.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mobuzon CI brief — competitive landscape report
Mobuzon updates RSS · CI watch RSS

Frequently asked questions about Mobuzon

What is Mobuzon?

Mobuzon (MOFEBUTAZONE) is a mofebutazone drug.

How does Mobuzon work?

Mofebutazone works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

What is the generic name of Mobuzon?

MOFEBUTAZONE is the generic (nonproprietary) name of Mobuzon.

What drug class is Mobuzon in?

Mobuzon belongs to the mofebutazone class. See all mofebutazone drugs at /class/mofebutazone.

What development phase is Mobuzon in?

Mobuzon is in Phase 2.

Drug class: All mofebutazone drugs
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing